(Sharecast News) - Fusion Antibodies said on Thursday that it expects a stronger performance in the second half of the year after reporting first-half revenues of £0.84m, as operational efficiency improved and market sentiment began to recover.
The AIM-traded antibody discovery and engineering specialist said unaudited revenue for the six months...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE